In the world of tech investing, it’s practically a catchphrase.

Nvidia has been doing something uncommon in Silicon Valley history for the past few years. The business not only profited from a technological revolution, but it also served as its catalyst. Originally created for video games, its graphics processing units are now used to run massive artificial intelligence models in data centers all over the world. Investors were left staring at charts that resembled mountain cliffs rather than stock performance as Nvidia’s valuation skyrocketed.

The hunt has started, of course.

The same question is being asked by retail traders, venture capitalists, and Wall Street analysts. Who will follow Nvidia if it emerges as the key player in the AI era? It’s an alluring concept. According to history, a new giant is always emerging somewhere, just out of sight.

These days, a peculiar blend of impatience and excitement can be seen when strolling through venture offices in Palo Alto or Midtown Manhattan. Investors discuss chip startups in the same way that early internet investors discussed browser companies. It’s a familiar atmosphere. It resembles the late 1990s, when everyone was speculating about which company would control the internet economy. Many of the guesses made back then were incorrect.

The unexpectedness of Nvidia’s dominance contributes to its allure. For many years, the company was primarily recognized by computer graphics engineers and gamers. Few people, even in Silicon Valley, could have predicted that GPUs would become the central component of artificial intelligence.

However, Nvidia appeared less like a graphics company and more like the infrastructure of the digital age once big AI models started training on enormous clusters of chips.

Everything was altered by that change.

Investors now appear to be certain that the next trillion-dollar opportunity will appear somewhere along the same supply chain. However, it’s still unclear exactly where that opportunity is. Custom AI processors, or chips made for particular models rather than general computing, are thought to be the cause. Others contend that the true winners might be found further down the infrastructure, providing massive AI data centers with memory, networking, or even power.

The next Nvidia might not even look like Nvidia.

Think about Broadcom, a business that subtly controls the market for custom ASIC chips. Its processors are made especially for hyperscale businesses developing massive AI systems. Artificial intelligence-related revenue has been increasing quickly; some executives estimate that sales of AI chips will reach tens of billions of dollars annually in a few years.

The story is still far from resolved, though.

Another possibility is beginning to emerge inside data center construction sites throughout the American Southwest. Massive amounts of electricity are used in AI computing. It becomes clear that the true limitation might not be chips at all when you stand outside one of these facilities at dusk, with rows of gray cooling towers humming softly. Perhaps it’s power.

Investors are starting to take notice.

Some hedge fund managers now discuss energy infrastructure firms with the same zeal that they used to reserve for software startups. It’s not glitzy. However, the economics start to make sense when a single AI facility can consume as much electricity as a small city.

The market might still be underestimating how tangible this AI revolution is.

As the frenzy develops, it’s difficult to ignore how quickly tech investing narratives take shape. The natural response was to imitate Nvidia’s success once it became evident. Look for a different chip manufacturer. Support the upcoming GPU champion. Hold off until the stock chart repeats itself. However, technological advancements are rarely linear.

While the largest profits surfaced in the fiber-optic networks, semiconductor suppliers, and hardware companies that enabled the web, many investors pursued internet companies during the dot-com boom. It’s possible that something similar is happening once more.

Indeed, chips are necessary for artificial intelligence. However, it also requires a lot of electricity, data centers, networking hardware, memory, cooling systems, and rare metals.

It’s possible that the next giant is already developing somewhere within that network of infrastructure.

It appears that investors are aware of it. For this reason, the same agitated question can be heard in conference rooms, venture capital meetings, and trading desks.

Who will take over as Nvidia’s successor?

To be honest, no one truly knows. And maybe the search is so appealing because of that uncertainty. There’s a sense that the next chapter of this tale hasn’t been written yet as the AI economy grows, with factories constructing servers, engineers testing new chips, and investors poring over balance sheets late at night.

The post Tech Investors Are Searching for the Next Nvidia appeared first on Creative Learning Guild.

UBS has significantly raised its price target forecasts from HK$97.60 to HK$103.70. That wasn’t a casual move. Rather, it came after a series of positive signs, including an easing of stamp duty policy, a small uptick in home sales, and early indications that consumer confidence was returning to residential areas.

The current trajectory of Sun Hung Kai is especially intriguing because it hasn’t changed much. The corporation has always prioritized longevity, discipline, and caution in its strategy. SHKP maintained its concentration by carefully purchasing land, building at scale, and selecting a variety of residential, business, and retail properties that remained remarkably durable, while others pursued rapid growth into mainland territory.

The company positioned itself to weather volatility by keeping its gearing low and its liquidity high. And it seems to be enjoying the advantages presently. Amazingly, SHKP’s cash flow is so strong that it keeps paying out a dividend yield of almost 5%, which is a very alluring amount in a market when interest rates are rising.

When I went to a property investment seminar in early 2023, I noticed that analysts talking about Hong Kong’s residential market were clearly worn out. A number of presenters described the market as “structurally stagnant.” However, one voice—a quiet property fund manager—made an odd comment: “Pay attention to SHKP. They are aware of when to wait. I still remember that line.

In the present, it appears like patience is paying off.

Foot traffic in retail and commercial establishments has significantly increased. Regional tenants are consistently showing interest in offices in prime locations, and leasing patterns are rebounding throughout iconic shopping complexes. Not only is SHKP’s core portfolio surviving, but it is also continuously growing.

The business has grown quite effective at managing long-term leases and occupancy by concentrating on project execution and tenant relationships. Additionally, it has been growing green-certified projects, especially in mixed-use suburban areas. These projects are exceptionally creative because they combine real-time smart energy technology with sustainable design, a tactic that appeals to institutional investors looking for assets that will last.

By means of strategic alliances and prudent capital management, SHKP has grown precisely rather than quickly. It’s creating lasting value rather than chasing quarterly headlines. This strategy, which was often seen to be dull in exuberant markets, is now appearing quite sensible.

Investors are starting to use SHKP as a gauge of the overall health of the sector in light of the growing interest in Hong Kong’s recovery. And with good reason. It’s one of the few names that offers real upside potential together with scalability, resilience, and governance integrity.

Expectations are subtly rising in anticipation of March’s earnings. We might see another round of forecast modifications if the company reports better-than-expected pre-sales or indicates a change in inventory absorption across significant developments. If anything, it feels long overdue, so it wouldn’t be shocking.

0016 is for early-stage funds that want to balance their exposure to Asia.One such anchor stock is HK. Even while it might not double overnight, it provides consistency, yield, and the opportunity to participate in one of the most well-known real estate recoveries in the area. That combo is incredibly effective and getting harder to find.

Sun Hung Kai has positioned itself to go from being “overlooked” to “essential” in many model portfolios by enduring volatility and making forward-looking modifications without sacrificing its core values.

The post 0016 HK Stock Price Hits 52-Week High as Analysts Turn Bullish appeared first on Creative Learning Guild.

The proposal surprisingly weakened assumptions built into sector-wide appraisals by keeping reimbursements essentially unchanged. The cornerstone of the sector, UnitedHealth, lost over 20% of its value in a matter of hours. Closely behind were Humana and CVS Health. Despite having a little more insulation, Centene and Elevance were nevertheless affected.

Given that the underlying firms had done fairly well, the disruption felt especially abrupt. In its quarterly report, UnitedHealth reported strong fourth-quarter results. The report and the 2026 prognosis were deemed “sound” by analysts. However, policy uncertainty appears to have outperformed financial stability.

It was the size of the response that surprised many. Selling began after an apparently small shift in reimbursement expectations. A mid-single-digit gain was what analysts had predicted. It was necessary to recalibrate because the real figure was just above zero. The change in direction was more painful than the actual amount.

For health insurers, Medicare Advantage has grown to be a very profitable market in recent years. These plans, which provide a managed-care substitute for traditional Medicare, draw in millions of Americans and provide high-margin growth for companies that can effectively manage them.

However, the industry’s growth has obviously halted due to fresh scrutiny from the Department of Justice and CMS. Concerns regarding big insurers’ diagnosis coding procedures were brought up by investigative reports last year. The policy changes now appear to be in line with that rising uneasiness, even though UnitedHealth and other firms vehemently denied any misconduct.

There are other limitations on how diagnoses can be used to determine payment in the CMS proposal. In the past, condition data could be used by clinicians without a specific patient interaction. This flexibility could now be limited. It results in lower risk adjustment ratings, which in turn translate into lower payments for insurers.

The CEO of UnitedHealthcare, Tim Noel, expressed his annoyance. “Disappointing,” he said during the earnings call, the idea may lead to “very meaningful benefit reductions.” That was a really powerful statement, indicating that if margins are squeezed too much, service cuts could ensue.

But a more nuanced picture is beginning to emerge inside the sell-off. The industry is still robust structurally. Demographic changes and consumers’ growing reliance on managed care are driving up demand. Medicare Advantage is still a vital part of the federal healthcare agenda, despite stricter regulations.

As baby boomers age, the number of people who qualify for Medicare will continue to rise in the upcoming years. Advantage plans have already surpassed traditional Medicare in enrollment. It is difficult to reverse this trend.

Medicare Advantage is slow, dependable, and comparatively unaffected by headline shocks, according to one investor at a healthcare policy seminar I attended in 2023. As I watched this week’s sell-off, I thought back to that remark and how quickly the parallel had fallen apart.

However, long-term opportunities does not necessarily stop with that breakdown. It is possible that investors are overreacting to a preliminary rate, which usually gets adjusted upward prior to finalization. It’s also important to note that over the past five years, cost-containment initiatives throughout the industry have significantly improved, even though payments may grow more slowly.

The management of chronic illnesses has become surprisingly effective for insurers through the use of predictive modeling and improved care coordination. Due to the substantial decrease in needless hospital admissions brought about by these operational improvements, businesses are able to sustain profit margins even in situations with limited revenue.

One example of how diversification fosters durability is CVS Health, which combines retail clinics, pharmacy benefit management, and insurance. Others give ballast even while one arm is compressed. This also holds true for Elevance and Cigna, both of which have recently grown vertically to gain greater control over the treatment continuum.

Confidence, not demand, is what’s shifting right now. The amount of political risk that investors are ready to take on is shifting. Long viewed as protective investments, healthcare stocks are being reinterpreted. It no longer feels automatic that Medicare policy will be influenced by election-year politics.

The Trump administration’s justifications—protecting taxpayers and cutting expenses—make political sense. However, because it came at a time when voters were worried about government expenditure and inflation, there was an exceptionally strong response.

But history shows that stability frequently returns, even in the midst of volatility. After receiving criticism from patient advocacy organizations and insurers, CMS usually modifies its ideas. It will be months before the rates are finalized. Furthermore, few people think Congress will accept significant cuts to senior benefits before an election season because healthcare is such a politically sensitive area.

This allows businesses to adjust, improve their products, and rework expectations. The recent decline may provide long-term investors a surprisingly inexpensive entry point for businesses that are still strategically important and have excellent cash flow.

Perspective, not panic, is what’s important right now. The health insurance industry is adjusting to more stringent regulation. That only reshapes its worth rather than eliminating it. Performance is what drives the show, even though policy sets the scene.

These identical equities may show up much more quickly than their critics anticipate in recovering momentum in a few quarters. The basics—solid balance sheets, successful care models, and an expanding member base—remain remarkably evident.

In fact, the sell-off has made the industry more focused, especially on operational rigor and transparency. In the long term, such change may be especially advantageous—for patients, providers, and shareholders, above all.

The post Health Insurance Stocks Slide After Medicare Payment Freeze appeared first on Creative Learning Guild.